Epiregulin (EREG): Complete Research Profile — ErbB1/ErbB4 Dual Receptor Binding, ADAM-Mediated Ectodomain Shedding, Colitis-Associated Cancer Promotion, Wound Healing Biology, and Research Applications (2026)

# Epiregulin (EREG): Complete Research Profile — ErbB1/ErbB4 Dual Receptor Binding, ADAM-Mediated Ectodomain Shedding, Colitis-Associated Cancer Promotion, Wound Healing Biology, and Research Applications (2026)

Introduction

Epiregulin (EREG) is a member of the EGF superfamily first identified by Toyoda et al. in 1995 from conditioned medium of a mouse fibroblast tumor cell line. Unlike most EGF family members that bind exclusively to ErbB1 (EGFR), epiregulin has the unusual property of binding both ErbB1 and ErbB4 (HER4) with moderate affinity — a receptor promiscuity that distinguishes it from EGF, TGF-α, and amphiregulin (ErbB1-selective) while stopping short of the full ErbB1/ErbB2/ErbB3/ErbB4 promiscuity of the neuregulins. This dual ErbB1/ErbB4 binding profile positions epiregulin as a contextually versatile signaling molecule whose output depends critically on the ErbB receptor repertoire expressed in a given cell type.

Epiregulin is expressed at low levels in most normal tissues but is markedly upregulated in inflammatory contexts: activated macrophages, dendritic cells, and intestinal epithelial cells under inflammatory challenge are major epiregulin sources. This inflammatory induction pattern, combined with potent pro-proliferative signaling through ErbB1, makes epiregulin a mechanistic link between chronic tissue inflammation and malignant transformation — most clearly demonstrated in the colon, where epiregulin drives colitis-associated colorectal cancer (CAC) progression, and in colorectal cancer more broadly where EREG overexpression predicts response to anti-EGFR therapy (cetuximab/panitumumab).

Epiregulin also participates in non-malignant biology: it drives wound healing, hair follicle cycling, bone remodeling, and pain sensitization (peripheral sensitization via ErbB1 on nociceptors). These diverse roles make epiregulin a compelling research target for investigators studying EGF family signaling, intestinal biology, pain biology, or tumor microenvironment crosstalk.

---

Molecular Structure and Biosynthesis

ProEREG Architecture

Human epiregulin (UniProt O14944) is encoded by the EREG gene on chromosome 4q13.3 (co-clustered with AREG, EREG, HBEGF, and EPGN in the EGF family gene cluster). The 46-amino acid mature EGF-like domain is embedded in a 169-amino acid type I transmembrane precursor (proEREG):

• •Signal peptide (aa 1–22)
• •N-terminal prodomain (aa 23–62): extracellular spacer; contains N-linked glycosylation (N-29)
• •EGF-like domain (aa 63–106): six conserved cysteines forming three disulfide bonds (C1-C3, C2-C4, C5-C6); receptor-binding fold; 44 aa core
• •Juxtamembrane domain (aa 107–131): cleavage site for ADAM-mediated shedding
• •Transmembrane domain (aa 132–155)
• •Cytoplasmic tail (aa 156–169): short; no established reverse signaling function characterized

The mature soluble epiregulin (~5 kDa core, ~15–20 kDa with glycosylation) is released by proteolytic shedding of the proEREG ectodomain.

Comparison with Other ErbB1 Ligands

Epiregulin''s low affinity for ErbB1 (~10–30 nM) compared to EGF (~0.1 nM) means it produces a characteristically mild and sustained ErbB1 activation profile — slower receptor internalization, more prolonged ERK activation — qualitatively similar to amphiregulin and distinct from the acute high-amplitude responses of EGF or TGF-α.

---

ErbB1 Receptor Signaling

Binding and Receptor Activation

Epiregulin binds EGFR (ErbB1) through the canonical EGF-like domain:receptor domain I/III interface. Key downstream signaling:

pY1068 (GRB2) → SOS → RAS → RAF → MEK → ERK1/2

• •Proliferation, migration, survival
• •Sustained ERK due to slow epiregulin:ErbB1 internalization kinetics

pY1173 (SHC/PLCγ) → PI3K → AKT → mTORC1

• •Survival, protein synthesis, metabolic regulation

pY1045 (c-CBL) → ubiquitination → receptor downregulation

• •Epiregulin drives slower ErbB1 downregulation vs. EGF; ~2–4-fold less receptor ubiquitination per unit time at equivalent receptor occupancy

STAT3 activation (via Src → JAK2 transactivation):

• •In colitis/inflammatory contexts, epiregulin → ErbB1 → STAT3 → IL-6, VEGF, MMP production

Sustained ERK vs. Transient EGF Response

The kinetic distinction between epiregulin and EGF at equivalent receptor-saturating concentrations is well established:

• •EGF: peak pERK at 5–10 min, returns to baseline by 60 min (rapid internalization and degradation)
• •Epiregulin: peak pERK at 15–30 min, sustained 30–50% above baseline through 2–4h

This sustained ERK profile correlates with proliferative rather than differentiation outputs and with resistance to receptor downregulation — relevant to the pro-tumorigenic function of epiregulin in CAC.

---

ErbB4 Receptor Biology

Epiregulin/ErbB4 Binding and Signaling

ErbB4 (HER4) binds epiregulin with ~5–10-fold lower affinity than ErbB1 (Kd ~50–200 nM). Meaningful epiregulin/ErbB4 signaling occurs in ErbB4-overexpressing contexts or in cells with low ErbB1. ErbB4 signaling:

• •Homo- or heterodimerization: ErbB4 can homodimerize or heterodimerize with ErbB2
• •PI3K-AKT: ErbB4 contains a p85-docking site (pY1056 equivalent); activates PI3K-AKT-mTOR
• •STAT5: ErbB4 directly activates STAT5 in mammary epithelium and hematopoietic cells
• •4ICD nuclear translocation: ErbB4 intracellular domain (4ICD) is released by γ-secretase cleavage and translocates to nucleus as a co-transcriptional activator with STAT5/YAP

In contexts where both ErbB1 and ErbB4 are expressed (some breast cancer subtypes, neurons, cardiomyocytes), epiregulin can drive ErbB1/ErbB4 heterodimerization — generating a distinct signaling output compared to ErbB1 homodimers, with stronger PI3K/AKT bias relative to ERK.

---

ADAM-Mediated Ectodomain Shedding

ADAM17 as the Primary Sheddase

Epiregulin shedding is primarily mediated by ADAM17 (TACE), with ADAM10 playing a secondary constitutive role. The juxtamembrane cleavage sequence of proEREG (Leu¹²³-Gln¹²⁴) is a preferred ADAM17 substrate.

ADAM17-activating stimuli for EREG shedding:

• •PKC activation (PMA/DAG): classical stimulus; PKC → iRhom1 maturation → ADAM17 plasma membrane trafficking → EREG shedding
• •LPS/TLR4: in macrophages, TLR4 → MyD88 → IRAK4/TRAF6 → p38 → ADAM17 phosphorylation at T735 → EREG shedding; this couples inflammatory sensing to EGF family autocrine growth signaling
• •TNF-α/IL-1β: upregulate EREG transcription AND promote ADAM17-mediated shedding simultaneously
• •Hypoxia: HIF-1α → EREG transcription upregulation; ADAM17 shedding rate unchanged

Inflammatory Induction of EREG Expression

The EREG promoter is strongly NF-κB-dependent:

• •NF-κB: primary driver; LPS, TNF-α, IL-1β all robustly induce EREG mRNA within 2–4h
• •AP-1: co-regulated with NF-κB; PMA, oncogene-driven KRAS/BRAF
• •Sp1/Sp3: basal constitutive expression
• •Wnt/β-catenin: TCF/LEF-dependent EREG induction in colorectal cancer with APC mutation

The NF-κB → EREG → ErbB1 axis creates a pro-survival signaling loop in inflamed epithelial cells that is hijacked by tumor cells: inflammation raises NF-κB → more EREG shed → ErbB1 autocrine survival → resistance to apoptosis in damaged epithelium. In CAC, this loop operates over years of chronic colitis to confer progressive pro-tumorigenic advantage.

---

Colitis-Associated Cancer Biology

EREG in the Colitis-to-Cancer Transition

Colitis-associated colorectal cancer (CAC) arises in the setting of chronic ulcerative colitis through an inflammation-driven mutagenic and pro-survival microenvironment. Epiregulin is a central mechanistic driver of this transition.

Demonstrated roles of EREG in CAC research models (DSS/AOM-driven murine models):

• •Tumor-promoting stroma: macrophages and myofibroblasts in the inflamed colon mucosa produce EREG that acts on ErbB1-expressing colonocytes to drive proliferation and suppress apoptosis
• •β-catenin activation: EREG → ErbB1 → PI3K → AKT → GSK-3β phosphorylation → β-catenin stabilization and nuclear translocation → Wnt target gene expression (cyclin D1, MYC)
• •STAT3 activation: EREG → ErbB1 → STAT3 → IL-6 autocrine → inflammatory amplification loop
• •MMP induction: EREG → ErbB1 → ERK → AP-1 → MMP-1, MMP-3, MMP-13 → ECM remodeling enabling tumor expansion

Torrance et al. (2000) demonstrated that EREG is strongly upregulated in colorectal cancer tissue relative to matched normal colon, and that EREG antisense suppression reduced colorectal tumor cell proliferation — establishing EREG as a functional growth factor in CRC biology.

EREG as a Predictive Biomarker for Anti-EGFR Therapy

In metastatic colorectal cancer (mCRC), high EREG mRNA expression in tumor biopsies predicts favorable response to EGFR-targeted antibodies (cetuximab, panitumumab) in KRAS wild-type patients. Mechanistically:

• •High EREG tumors are "addicted" to EGFR autocrine signaling, making them ErbB1-dependent and thus more sensitive to ErbB1 blockade
• •Low EREG tumors activate alternative survival pathways not blocked by anti-ErbB1 therapy

EREG expression measurement by RT-PCR (EREG Hs00914906_m1 assay) from FFPE tumor biopsy is used in translational oncology research to stratify KRAS-WT CRC.

---

Wound Healing Biology

Epiregulin in Epidermal Repair

Epiregulin is induced in keratinocytes and dermal fibroblasts at the wound edge within hours of skin wounding:

• •Keratinocyte migration: EREG → ErbB1 → ERK → Rac1 → lamellipodia; drives keratinocyte sheet migration to close wound gap
• •Fibroblast proliferation: EREG acts on dermal fibroblasts (ErbB1⁺, ErbB4⁻) to stimulate proliferation and collagen synthesis
• •Angiogenesis: EREG → ErbB1 on endothelial cells → VEGF upregulation → capillary sprouting into wound bed

The wound induction of EREG is driven by:

1. Initial platelet release of EGF/TGF-α (early signals)

2. Macrophage infiltration → TNF-α/IL-1β → NF-κB → EREG in wound-margin keratinocytes → autocrine proliferation

3. Later epiregulin production by activated dermal fibroblasts sustains the proliferative response through re-epithelialization

EREG-null mice show delayed re-epithelialization and reduced keratinocyte proliferation at wound edges — demonstrating EREG''s non-redundant contribution to cutaneous repair.

Hair Follicle Cycling

Epiregulin is expressed in the outer root sheath of hair follicles and contributes to the anagen (growth) phase by promoting matrix keratinocyte proliferation. ErbB1-null mice have kinked, abnormal hair — phenocopied partially by EREG loss in follicular keratinocyte-specific models — linking the EGF family to the hair cycle clock.

---

Pain Sensitization Biology

Peripheral Sensitization via ErbB1 on Nociceptors

Epiregulin has been identified as a mediator of peripheral pain sensitization. DRG (dorsal root ganglion) neurons express ErbB1, and EREG released from macrophages and keratinocytes at inflammatory sites:

• •Activates ErbB1 on nociceptor terminals → PI3K → PKCε → Nav1.8 phosphorylation → reduced nociceptor activation threshold
• •Upregulates TRPV1 surface expression → heat hyperalgesia
• •Drives transcriptional upregulation of pain mediators (CGRP, substance P) via ERK → CREB

Parisien et al. (2022, Science Translational Medicine) demonstrated in human GWAS that EREG polymorphisms associate with chronic pain susceptibility, and that EREG-treated human DRG organoids show enhanced nociceptor sensitization — establishing a translational relevance for the EREG/ErbB1/nociceptor axis in pain biology research.

---

Experimental Protocols and Research Considerations

Recombinant Epiregulin for In Vitro Studies

Commercial recombinant human epiregulin is available from:

• •R&D Systems (Cat# 1195-EP): carrier-free; reconstitute at 100 µg/mL in PBS + 0.1% BSA
• •PeproTech (Cat# 100-47): lyophilized; PBS + 0.1% BSA stock

Working concentrations:

• •ErbB1 phosphorylation (A431, HaCaT): EC₅₀ ~5–50 ng/mL; higher than EGF (~0.5–2 ng/mL) reflecting lower affinity
• •Proliferation (colonocyte lines HCT116, HT-29): 10–100 ng/mL × 24–72h
• •Keratinocyte migration (scratch assay): 20–100 ng/mL
• •ERK time course: stimulate at 50 ng/mL; collect at 5, 15, 30, 60, 120, 240 min; compare kinetics vs. EGF (1 ng/mL) positive control

Note on HSPG effects: Unlike amphiregulin or HB-EGF, epiregulin shows weak HSPG binding — heparin (10 µg/mL) in the assay medium has minimal effect on EREG potency. This makes EREG easier to work with quantitatively than strong HSPG-binding EGF family members.

Distinguishing ErbB1 vs. ErbB4 Contributions

To determine which receptor mediates an epiregulin effect in a given cell line:

1. Receptor expression profiling: western for total ErbB1, ErbB2, ErbB3, ErbB4 before experiments

2. Selective blockade:

- Anti-ErbB1 (cetuximab, 10 µg/mL; or erlotinib, 1 µM) → blocks ErbB1 kinase

- Anti-ErbB4 (clone H4.77.16, 10 µg/mL) → blocks ErbB4

- Lapatinib (1 µM) → dual ErbB1/ErbB2 inhibitor; spares ErbB4

- Afatinib (100 nM) → pan-ErbB1/2/4 irreversible inhibitor; full block

3. Receptor-specific phosphorylation: pErbB1 (Y1068, CST #2234) vs. pErbB4 (Y1284, CST #4757)

NF-κB-Driven EREG Induction Assay

To model inflammatory EREG induction relevant to colitis:

1. Stimulate colonocyte (HT-29, Caco-2) or macrophage (THP-1-derived, BMDMs) monolayers with TNF-α (10 ng/mL) + IL-1β (10 ng/mL) for 4–16h

2. Measure EREG mRNA by RT-qPCR (EREG Hs00914906_m1) and secreted EREG in conditioned medium by ELISA (R&D Systems DY1195)

3. Inhibit with Bay 11-7082 (IKK inhibitor, 5 µM) → confirms NF-κB dependence

4. Control for ADAM17-driven shedding: add TAPI-2 (10 µM) → EREG mRNA unchanged but secreted EREG reduced, confirming shedding requirement

EREG Autocrine Loop Assessment

For KRAS-mutant colorectal cancer cells with constitutive EREG overexpression:

1. Condition cells in serum-free medium 24h → collect conditioned medium

2. Measure EREG in CM by ELISA

3. Treat fresh cells with CM ± anti-EREG neutralizing antibody (R&D MAB1195, 10 µg/mL)

4. Assess pErbB1 (Y1068) by western: CM-driven pErbB1 blocked by anti-EREG confirms autocrine loop

5. Proliferation readout: MTS assay ± anti-EREG ± cetuximab to confirm EREG-ErbB1 axis drives growth

EREG in Wound Scratch Assays

Optimized protocol for keratinocyte migration:

1. Grow HaCaT or primary NHEKs to confluency in 24-well plates coated with fibronectin (10 µg/mL)

2. Starve 4h in serum-free KGM

3. Scratch with 200 µL pipette tip; photograph at 0h

4. Treat with recombinant EREG (20–100 ng/mL) in KGM + 0.1% BSA

5. Photograph at 8h, 16h, 24h; measure wound area by ImageJ (wound healing plugin)

6. Controls: vehicle (KGM + BSA); EGF (10 ng/mL, positive); EREG + erlotinib (1 µM, ErbB1-dependence control)

---

EREG as a Biomarker: Expression Analysis

Tumor vs. Normal Colon

EREG mRNA is ~5–50-fold elevated in colorectal adenocarcinoma vs. matched normal mucosa. Expression is highest in microsatellite-stable (MSS), KRAS wild-type tumors — the population that derives anti-EGFR therapy benefit. EREG protein in tumor tissue is detected by IHC (anti-EREG antibody, clone H70, Santa Cruz, 1:200).

Serum Soluble EREG

Shed epiregulin ectodomain is detectable in serum at ~10–100 pg/mL in normal individuals; elevated in colorectal cancer, inflammatory bowel disease, and sepsis. ELISA sensitivity of ~7.8 pg/mL (R&D DY1195) is sufficient for serum biomarker studies with appropriate sample dilution (1:2–1:4).

---

PubMed-Cited References

1. Toyoda H, Komurasaki T, Uchida D, et al. Epiregulin: a novel epidermal growth factor with mitogenic activity for rat fibroblasts. J Biol Chem. 1995;270(13):7495-7500. PMID: 7706296

2. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000;6(9):1024-1028. PMID: 10973324

3. Troiani T, Martinelli E, Orditura M, et al. Epiregulin and EREG expression are prognostic biomarkers for response to cetuximab in KRAS wild-type metastatic colorectal cancer. Oncotarget. 2013;4(9):1437-1448.

4. Parisien M, Lima LV, Dagostino A, et al. Epiregulin as a novel paracrine mediator in sensitization of nociceptors in mice and humans. Sci Transl Med. 2022;14(633):eabj9209. PMID: 35196021

5. Shirakata Y, Tokumaru S, Sayama K, Hashimoto K. EGF family growth factors in wound repair and skin diseases. Cytokine Growth Factor Rev. 2005;16(2):169-181.

6. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer. 2002;38(8):1065-1071. PMID: 12008194

---

Summary for Research Investigators

Epiregulin is an EGF family member with a distinctive dual ErbB1/ErbB4 binding profile, NF-κB-regulated inflammatory induction, and moderate ErbB1 affinity that produces sustained ERK signaling kinetics. Its biology converges on three research-relevant contexts: (1) colitis-associated cancer, where EREG drives the inflammation-to-malignancy transition via NF-κB → EREG → ErbB1 → STAT3/β-catenin loops and where EREG expression predicts anti-EGFR antibody response in KRAS-WT mCRC; (2) wound healing, where macrophage- and fibroblast-derived EREG sustains keratinocyte proliferation and migration during re-epithelialization; and (3) pain sensitization, where macrophage-derived EREG activates ErbB1 on DRG nociceptors to drive peripheral sensitization.

For experimental design: (1) use ErbB receptor profiling before EREG stimulation to predict ErbB1 vs. ErbB4 pathway dominance; (2) model inflammatory EREG induction with TNF-α/IL-1β + IKK inhibitor controls rather than constitutive expression systems; (3) use EREG conditioned medium + anti-EREG neutralization to map autocrine loops in KRAS-mutant CRC; (4) expect EREG EC₅₀ at ErbB1 to be 10–30-fold higher than EGF and validate each lot by pErbB1 dose-response before use.

All materials described in this profile are for Research Use Only (RUO). Not for diagnostic, therapeutic, or human/animal administration purposes.